Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
1. Moderna missed EPS estimates at $(2.91) versus $(2.62) consensus. 2. Quarterly sales dropped to $966 million from $2.81 billion year-over-year. 3. The Phase 3 study on norovirus vaccine is on hold due to GBS report. 4. Barclays downgrades Moderna's rating and lowers price target to $45. 5. Analysts maintain mixed ratings but expect 52.24% upside for MRNA stock.